Peps
What is Cagrilintide?
Cagrilintide is an amylin analogue investigated for weight management. Its evidence must be separated from evidence for combinations containing it.
Biological role or research focus
Amylin signaling and appetite research.
Cagrilintide alone and CagriSema, the combination with semaglutide, are different study treatments.
Names you may encounter
CagriSema
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Long-acting amylin analogue
- Main research area
- Satiety and weight management research
- Evidence featured
- Human phase 2 trial
- Source check
- October 4, 2026
Molecular structure
Mechanism & research rationale
Amylin is a pancreatic satiety signal. Cagrilintide was designed to provide longer-lasting activity, and clinical development tests whether that signaling translates into sustained weight reduction.
Research context & status
The selected study evaluates cagrilintide alone. CagriSema combines cagrilintide with semaglutide and has a separate clinical development program. This page does not present a trial record as a product approval.
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human phase 2 trial · 2021
Cagrilintide dose-finding study
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
- Population / model
- 706 adults with obesity, or overweight with hypertension or dyslipidemia, without diabetes.
- Study design
- 26 weeks; placebo and liraglutide comparators; participants were not blinded between different active treatments.
- Main finding
- Estimated mean weight reduction ranged from 6.0% to 10.8% across cagrilintide groups versus 3.0% with placebo in the trial-product analysis. Gastrointestinal and injection-site events were frequent.
- Limits & context
- This is monotherapy evidence. It cannot be presented as the result for CagriSema or for an unidentified seller blend; longer-term outcomes require separate studies.
Human phase 3 randomized trial · 2025
REDEFINE 1 · CagriSema
What did the combination achieve in adults without diabetes?
- Population / model
- 3,417 adults with obesity, or overweight with an obesity-related complication, without diabetes.
- Study design
- 68-week blinded trial of the combination, each component separately, or placebo; all groups received lifestyle intervention.
- Main finding
- Estimated weight change was −20.4% with the combination versus −3.0% with placebo under the treatment-policy analysis. Gastrointestinal events occurred in 79.6% versus 39.9%.
- How to read it
- These headline results concern cagrilintide plus semaglutide, not cagrilintide alone.
- Limits & context
- The analysis includes treatment discontinuation. Different estimands can produce different headlines. It does not establish long-term cardiovascular benefit or equivalence to a seller blend. Funded by Novo Nordisk.
Source: REDEFINE 1 · CagriSema · 2025 ↗
Human phase 3 randomized trial · 2025
REDEFINE 2 · CagriSema in diabetes
How did the combination perform in a separate diabetes population?
- Population / model
- 1,206 adults with type 2 diabetes and BMI of at least 27.
- Study design
- 68-week blinded comparison of the combination with placebo, alongside lifestyle intervention; treatment-policy analysis.
- Main finding
- Estimated weight change was −13.7% versus −3.4%. HbA1c of 6.5% or lower was reached by 73.5% versus 15.9%. Gastrointestinal events occurred in 72.5% versus 34.4%.
- How to read it
- This population and comparator differ from REDEFINE 1; the percentages are not a direct head-to-head comparison.
- Limits & context
- Without separate component arms, this trial cannot isolate cagrilintide’s contribution. Weight and glucose endpoints do not prove longer survival or validate research-use mixtures. Funded by Novo Nordisk.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Search additional PubMed records ↗New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Safety evidence & remaining uncertainty
Gastrointestinal symptoms and injection-site reactions occurred in the phase 2 trial. A relatively short study cannot resolve uncommon harms or tolerability over many years.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
11 matching video records · 1 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
Fouad Abiad Media
RETATRUTIDE: EVERYTHING YOU NEED TO KNOW | Wes Christensen | Fouad Abiad's Real Bodybuilding Podcast ↗
Captions indexed · Automatic matches need review
Biohackingturkey
#peptidtedavisi #peptit #antiaging #cagrilintide ↗
Title match · Captions not indexed
Biohackingturkey
Cagrilintide Gerçekten Etkili mi? Bilim Ne Diyor? ↗
Title match · Captions not indexed
Biohackingturkey
Cagrilintide Nedir? Amilin Taklidi Peptit ile Obezite Tedavisi ↗
Title match · Captions not indexed
Biohackingturkey
Cagrilintide Nedir? Wegovy ve Ozempic’ten Daha mı Etkili? ↗
Title match · Captions not indexed
Biohackingturkey
Cagrilintide Nedir? Yeni Zayıflama İlacı Hakkında Her Şey ↗
Title match · Captions not indexed
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Is this cagrilintide alone or the CagriSema combination?
- Are results available, or is the claim based only on a trial plan?
- Cagrilintide alone and CagriSema, the combination with semaglutide, are different study treatments.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is CagriSema simply another name for cagrilintide?
No. It is a combination with semaglutide; its efficacy and safety require separate evidence.
Can the best group average predict an individual result?
No. A group average depends on the study population, adherence, duration, and analysis; individuals vary.
References & editorial record
- ClinicalTrials.gov · REDEFINE 3 ↗
- PubMed · Human phase 2 trial · PMID 34798060 ↗
- REDEFINE 1 · CagriSema · 2025 ↗
- REDEFINE 2 · CagriSema in diabetes · 2025 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.